The Silexion Therapeutics Corp (SLXN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a clinical-stage biotechnology issuer listed on the Nasdaq Capital Market. Silexion files current reports on Form 8-K, registration statements, and other documents that describe its RNA interference (RNAi) programs for KRAS-driven cancers, financing activities, and corporate developments.
Through its Form 8-K filings, Silexion furnishes press releases on key events such as positive preclinical data for its lead siRNA candidate SIL204, completion of toxicology studies, written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on its planned Phase 2/3 trial in locally advanced pancreatic cancer, and submission of a clinical trial application in Israel. Other 8-Ks detail capital-raising transactions, including public offerings and an at-the-market offering agreement, as well as Nasdaq correspondence confirming restoration of compliance with minimum bid price and shareholders’ equity listing requirements.
Investors can also review registration statements such as the Form S-1, which outlines Silexion’s status as a Cayman Islands–incorporated emerging growth company, its ordinary share and warrant structures, and risk disclosures associated with its clinical-stage oncology business. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide additional information on research and development expenses, general and administrative costs, and accumulated deficit.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand new financings, regulatory milestones, and material agreements. Real-time updates from EDGAR, along with structured access to Forms 8-K, registration statements, and other filings, allow users to track how Silexion describes its KRAS-focused RNAi pipeline, clinical plans for SIL204, and capital resources in its official SEC disclosures.
Silexion Therapeutics Corp, a Cayman Islands clinical-stage oncology company focused on RNA interference therapies for KRAS-driven cancers, has filed an amended Form S-1 for a primary best-efforts offering of up to 2,673,796 ordinary shares, each sold together with one ordinary warrant. Investors who would otherwise exceed 4.99% (or 9.99%) ownership may instead buy pre-funded warrants, priced at an assumed $1.8699 with a $0.0001 exercise price, each paired with an ordinary warrant.
Assuming the maximum shares are sold at an assumed $1.87 per share and no pre-funded warrants or warrant exercises, Silexion estimates net proceeds of about $4.3 million to fund pre-clinical and clinical studies, including its Phase 2/3 trial of lead candidate SIL204 in locally advanced pancreatic cancer, and for general corporate purposes. There is no minimum offering amount and no escrow, and H.C. Wainwright & Co. is acting as exclusive placement agent on a reasonable best-efforts basis.
The company had $2.4 million in cash and an accumulated deficit of $57.9 million as of March 31, 2026, with its auditor raising substantial doubt about its ability to continue as a going concern. Silexion is also working to restore and maintain compliance with the Nasdaq Capital Market’s $2.5 million shareholders’ equity requirement, and warns that failure to do so could lead to delisting.
Silexion Therapeutics Corp furnished an updated corporate presentation outlining development plans for its lead siRNA oncology candidate SIL204, which targets KRAS-driven tumors such as locally advanced pancreatic cancer. The program’s Phase 2/3 clinical trial in locally advanced pancreatic cancer was initiated in July 2026 after regulatory approvals in Israel and Germany, using a dual intratumoral and subcutaneous dosing strategy.
The presentation highlights preclinical data showing broad KRAS silencing at sub-nanomolar concentrations, tumor growth inhibition in mouse models, and established safety margins of up to 11-fold over the clinical starting dose in GLP toxicology studies with no systemic organ toxicity. The Phase 2/3 design includes a small safety run-in (about 15–18 patients) followed by randomized segments enrolling approximately 166 and 222 patients. Early human data are expected in Q4 2026, with an IND submission planned for Q1 2027 to expand the program to the U.S. and additional EU countries.
Silexion Therapeutics Corp. is a clinical-stage oncology biotech developing RNA interference therapies for KRAS-driven cancers. Lead candidate SIL204, a second-generation siRNA for locally advanced pancreatic cancer, combines intratumoral and subcutaneous dosing with chemotherapy. Regulators in Israel and Germany approved initiation of a Phase 2/3 trial, and the first site in Tel Aviv began operations in late July 2026.
The company plans a best-efforts primary offering of units consisting of ordinary shares or pre-funded warrants, each paired with an ordinary warrant, plus placement agent warrants, and is registering the ordinary shares underlying these instruments. Ordinary shares and publicly traded warrants list on Nasdaq as “SLXN” and “SLXNW”; on August 6, 2026 they closed at $1.79 and $0.020, with 1,349,019 ordinary shares outstanding before the offering.
Silexion is pre-revenue and reported a net loss of $11.9 million in 2025 and $2.7 million for the quarter ended March 31, 2026, with an accumulated deficit of $57.9 million and cash of $2.4 million. Auditors highlighted substantial doubt about its ability to continue as a going concern. The company has relied on multiple reverse share splits, warrant inducement financings, and conversions of a sponsor promissory note originally totaling $3.433 million (reduced to $956 thousand) to restore and maintain Nasdaq listing compliance, and it expects to need substantial additional capital.
Silexion Therapeutics Corp reported new preclinical data for SIL204, an RNAi therapy targeting KRAS-driven cancers. In human pancreatic and non-small cell lung cancer cell lines with KRAS G12D, G12V, and G12C mutations, SIL204 increased expression of the immune death receptor FAS and reduced expression of the immune checkpoint HLA-G, both in a statistically significant, dose-dependent manner.
Together with previously reported MHC-I upregulation in KRAS G12R-mutant pancreatic cells, the findings suggest a coordinated immune-sensitization profile across four KRAS mutations and three immune pathways: antigen presentation, apoptosis sensitivity, and checkpoint reduction. Silexion is advancing SIL204 into Phase 2/3 clinical evaluation, following initiation of its first clinical trial site at Tel Aviv Sourasky Medical Center in July 2026.
Silexion Therapeutics Corp reported changes to its Board and audit committee. Professor Amnon Peled notified the Board of his resignation from the Board and all committees, including the audit committee, effective August 1, 2026. His resignation was for personal reasons and did not result from any disagreement regarding the company’s operations, policies, or practices.
Immediately upon his resignation becoming effective, the Board appointed existing independent director Avner Lushi to the audit committee, filling the vacancy. The Board determined that Lushi meets the independence standards of Nasdaq Listing Rule 5605(c)(2)(A) and SEC Rule 10A-3(b)(1). With his appointment, the audit committee now consists of three independent members—Dror J. Abramov (chair and audit committee financial expert), Ruth Alon, and Lushi—restoring full compliance with Nasdaq’s audit committee composition requirements without using the cure period.
Silexion Therapeutics Corp, a Cayman Islands company with Ordinary Shares and warrants listed on The Nasdaq Stock Market, reported a change in its Board of Directors. On July 30, 2026, Professor Amnon Peled notified the Board of his resignation as a director.
His resignation is for personal reasons and will be effective as of August 1, 2026. The company reports that his decision did not arise from any disagreement with Silexion regarding its operations, policies, or practices.
Silexion Therapeutics Corp. announced the successful initiation of its Phase 2/3 clinical trial of SIL204, a small interfering RNA (siRNA) candidate, in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, formally activating the first clinical site and clearing it to begin patient screening, with first dosing anticipated afterward.
The trial evaluates SIL204 plus standard-of-care chemotherapy using a dual-route strategy that combines intratumoral delivery to overcome stromal barriers with systemic administration to address metastatic disease. It begins with an initial safety run-in of approximately 18 patients, then expands globally to a randomized cohort of approximately 166 patients. SIL204 is designed to silence a broad range of KRAS mutations, which occur in about 90% of pancreatic cancers, 45% of colorectal cancers, and 30–35% of lung adenocarcinomas, supporting potential use across multiple KRAS-driven tumors.
Silexion Therapeutics Corp reported that at its reconvened extraordinary general meeting on July 20, 2026, shareholders approved changes affecting warrants and share capital. The meeting initially lacked a standard quorum, but under the company’s articles, shareholders present after a half hour constituted a valid quorum.
Holders of 230,276 ordinary shares, representing 21.7% of issued and outstanding ordinary shares, were present in person or by proxy. A New Warrant Exercisability Proposal passed with 214,091 votes (93.3%) in favor and 15,293 against. An Authorized Share Capital Increase Proposal passed with 205,551 votes (89.8%) in favor and 23,382 against. The associated Memorandum Amendment, which increases authorized share capital, became effective when filed in the Cayman Islands on July 21, 2026.
Silexion Therapeutics Corp’s major holder has updated its ownership report. Moringa Sponsor, Moringa Partners Ltd and Ilan Levin together report beneficial ownership of 199,053 ordinary shares, representing 10.6% of Silexion’s ordinary shares, based on 1,877,696 shares outstanding as disclosed in a Form S‑3.
The filing details share issuances of 45,000, 92,500 and 60,819 ordinary shares that Silexion reported as issued to Moringa Sponsor upon conversion of an Amended and Restated Promissory Note originally totaling $3.4 million, including conversions of $1.8 million and two tranches of $0.4 million each. The reporting persons state they dispute the validity of these particular share issuances and do not concede beneficial ownership of those shares, and they characterize this amendment as being filed out of an abundance of caution.